Global Tissue Diagnostics

Tissue Diagnostics Comprehensive Study by Type (Consumables(Antibodies Kits, Reagents, Probes), Instruments (Slide Staining System, Scanner)), Application (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer (NSCLC), Other Diseases), Technology (Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology and Workflow Management, Special Staining), End User (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Research Laboratories) Players and Region - Global Market Outlook to 2028

Tissue Diagnostics Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 6.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Tissue Diagnostics?
Tissue diagnostic performs a crucial part in the diagnosis, monitoring and supervision of cancer disease. Tissue diagnostics is also applied for the diagnosis of next-generation sequencing, decoding cancer molecular profiles and circulating tumour cells. It is done by fine-needle aspiration cytology, open biopsy and core biopsy. The extent to which cancer has penetrated the healthy tissue, stage and type of cancer can be determined with the help of biopsy. This diagnostic is used in pharmaceutical companies, contract research organizations, research laboratories and hospitals for the diagnosis of cancer. Some of the major tissue diagnostic tests are immunohistocheistry (IHC), hexatoxylin & eosin (H&E) and others.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Billion)
Key Companies ProfiledRoche (Switzerland), Danaher (United States), Thermo Fisher Scientific (United States), Abbott (United States), Agilent Technologies (United States), ABCAM (United Kingdom), Merck KGAA (Germany), BD (United States), Hologic (United States) and Qiagen (Germany)
CAGR6.2%


The Global Tissue Diagnostics market is expected to see growth rate of 6.2% and may see market size of USD7.12 Billion by 2028.The Market is currently pegged at USD4.7 Billion. The study covers a detailed analysis segmented by key business segments i.e. by type (Consumables(Antibodies Kits, Reagents, Probes) and Instruments (Slide Staining System, Scanner)) , by application (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Diseases) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Tissue Diagnostics market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Tissue Diagnostics market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Roche (Switzerland), Danaher (United States), Thermo Fisher Scientific (United States), Abbott (United States), Agilent Technologies (United States), ABCAM (United Kingdom), Merck KGAA (Germany), BD (United States), Hologic (United States) and Qiagen (Germany).

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Influencing Trend:
Ongoing innovation and technological advancement on tissue diagnostics

Market Growth Drivers:
The growing number of cancer incidence across the globe and Rising healthcare expenditure

Challenges:
Sringent regulatory requirements

Restraints:
High cost associated with the diagnostics procedures

Opportunities:
Growing demand for personalized medicines

Key highlights of the Global Tissue Diagnostics market Study:
• CAGR of the market during the forecast period 2022-2028
• In-depth information on growth factors that will accelerate the Tissue Diagnostics market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Tissue Diagnostics market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Tissue Diagnostics Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Tissue Diagnostics market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Tissue Diagnostics market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Tissue Diagnostics Providers, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • Consumables(Antibodies Kits, Reagents, Probes)
  • Instruments (Slide Staining System, Scanner)
By Application
  • Breast Cancer
  • Gastric Cancer
  • Lymphoma
  • Prostate Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Other Diseases
By Technology
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Digital Pathology and Workflow Management
  • Special Staining

By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Research Laboratories

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The growing number of cancer incidence across the globe
      • 3.2.2. Rising healthcare expenditure
    • 3.3. Market Challenges
      • 3.3.1. Sringent regulatory requirements
    • 3.4. Market Trends
      • 3.4.1. Ongoing innovation and technological advancement on tissue diagnostics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tissue Diagnostics, by Type, Application, Technology, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Tissue Diagnostics (Value)
      • 5.2.1. Global Tissue Diagnostics by: Type (Value)
        • 5.2.1.1. Consumables(Antibodies Kits, Reagents, Probes)
        • 5.2.1.2. Instruments (Slide Staining System, Scanner)
      • 5.2.2. Global Tissue Diagnostics by: Application (Value)
        • 5.2.2.1. Breast Cancer
        • 5.2.2.2. Gastric Cancer
        • 5.2.2.3. Lymphoma
        • 5.2.2.4. Prostate Cancer
        • 5.2.2.5. Non-Small Cell Lung Cancer (NSCLC)
        • 5.2.2.6. Other Diseases
      • 5.2.3. Global Tissue Diagnostics by: Technology (Value)
        • 5.2.3.1. Immunohistochemistry (IHC)
        • 5.2.3.2. In Situ Hybridization (ISH)
        • 5.2.3.3. Digital Pathology and Workflow Management
        • 5.2.3.4. Special Staining
      • 5.2.4. Global Tissue Diagnostics by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Ambulatory Surgical Centers
        • 5.2.4.3. Diagnostic Centers
        • 5.2.4.4. Research Laboratories
      • 5.2.5. Global Tissue Diagnostics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Tissue Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Danaher (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Agilent Technologies (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. ABCAM (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck KGAA (Germany)\
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. BD (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hologic (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Qiagen (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Tissue Diagnostics Sale, by Type, Application, Technology, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Tissue Diagnostics (Value)
      • 7.2.1. Global Tissue Diagnostics by: Type (Value)
        • 7.2.1.1. Consumables(Antibodies Kits, Reagents, Probes)
        • 7.2.1.2. Instruments (Slide Staining System, Scanner)
      • 7.2.2. Global Tissue Diagnostics by: Application (Value)
        • 7.2.2.1. Breast Cancer
        • 7.2.2.2. Gastric Cancer
        • 7.2.2.3. Lymphoma
        • 7.2.2.4. Prostate Cancer
        • 7.2.2.5. Non-Small Cell Lung Cancer (NSCLC)
        • 7.2.2.6. Other Diseases
      • 7.2.3. Global Tissue Diagnostics by: Technology (Value)
        • 7.2.3.1. Immunohistochemistry (IHC)
        • 7.2.3.2. In Situ Hybridization (ISH)
        • 7.2.3.3. Digital Pathology and Workflow Management
        • 7.2.3.4. Special Staining
      • 7.2.4. Global Tissue Diagnostics by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Ambulatory Surgical Centers
        • 7.2.4.3. Diagnostic Centers
        • 7.2.4.4. Research Laboratories
      • 7.2.5. Global Tissue Diagnostics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tissue Diagnostics: by Type(USD Billion)
  • Table 2. Tissue Diagnostics Consumables(Antibodies Kits, Reagents, Probes) , by Region USD Billion (2017-2022)
  • Table 3. Tissue Diagnostics Instruments (Slide Staining System, Scanner) , by Region USD Billion (2017-2022)
  • Table 4. Tissue Diagnostics: by Application(USD Billion)
  • Table 5. Tissue Diagnostics Breast Cancer , by Region USD Billion (2017-2022)
  • Table 6. Tissue Diagnostics Gastric Cancer , by Region USD Billion (2017-2022)
  • Table 7. Tissue Diagnostics Lymphoma , by Region USD Billion (2017-2022)
  • Table 8. Tissue Diagnostics Prostate Cancer , by Region USD Billion (2017-2022)
  • Table 9. Tissue Diagnostics Non-Small Cell Lung Cancer (NSCLC) , by Region USD Billion (2017-2022)
  • Table 10. Tissue Diagnostics Other Diseases , by Region USD Billion (2017-2022)
  • Table 11. Tissue Diagnostics: by Technology(USD Billion)
  • Table 12. Tissue Diagnostics Immunohistochemistry (IHC) , by Region USD Billion (2017-2022)
  • Table 13. Tissue Diagnostics In Situ Hybridization (ISH) , by Region USD Billion (2017-2022)
  • Table 14. Tissue Diagnostics Digital Pathology and Workflow Management , by Region USD Billion (2017-2022)
  • Table 15. Tissue Diagnostics Special Staining , by Region USD Billion (2017-2022)
  • Table 16. Tissue Diagnostics: by End User(USD Billion)
  • Table 17. Tissue Diagnostics Hospitals , by Region USD Billion (2017-2022)
  • Table 18. Tissue Diagnostics Ambulatory Surgical Centers , by Region USD Billion (2017-2022)
  • Table 19. Tissue Diagnostics Diagnostic Centers , by Region USD Billion (2017-2022)
  • Table 20. Tissue Diagnostics Research Laboratories , by Region USD Billion (2017-2022)
  • Table 21. South America Tissue Diagnostics, by Country USD Billion (2017-2022)
  • Table 22. South America Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 23. South America Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 24. South America Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 25. South America Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 26. Brazil Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 27. Brazil Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 28. Brazil Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 29. Brazil Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 30. Argentina Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 31. Argentina Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 32. Argentina Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 33. Argentina Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 34. Rest of South America Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 35. Rest of South America Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 36. Rest of South America Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 37. Rest of South America Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 38. Asia Pacific Tissue Diagnostics, by Country USD Billion (2017-2022)
  • Table 39. Asia Pacific Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 40. Asia Pacific Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 41. Asia Pacific Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 42. Asia Pacific Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 43. China Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 44. China Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 45. China Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 46. China Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 47. Japan Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 48. Japan Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 49. Japan Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 50. Japan Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 51. India Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 52. India Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 53. India Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 54. India Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 55. South Korea Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 56. South Korea Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 57. South Korea Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 58. South Korea Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 59. Taiwan Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 60. Taiwan Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 61. Taiwan Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 62. Taiwan Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 63. Australia Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 64. Australia Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 65. Australia Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 66. Australia Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 67. Rest of Asia-Pacific Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 68. Rest of Asia-Pacific Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 69. Rest of Asia-Pacific Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 70. Rest of Asia-Pacific Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 71. Europe Tissue Diagnostics, by Country USD Billion (2017-2022)
  • Table 72. Europe Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 73. Europe Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 74. Europe Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 75. Europe Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 76. Germany Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 77. Germany Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 78. Germany Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 79. Germany Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 80. France Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 81. France Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 82. France Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 83. France Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 84. Italy Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 85. Italy Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 86. Italy Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 87. Italy Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 88. United Kingdom Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 89. United Kingdom Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 90. United Kingdom Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 91. United Kingdom Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 92. Netherlands Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 93. Netherlands Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 94. Netherlands Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 95. Netherlands Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 96. Rest of Europe Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 97. Rest of Europe Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 98. Rest of Europe Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 99. Rest of Europe Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 100. MEA Tissue Diagnostics, by Country USD Billion (2017-2022)
  • Table 101. MEA Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 102. MEA Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 103. MEA Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 104. MEA Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 105. Middle East Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 106. Middle East Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 107. Middle East Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 108. Middle East Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 109. Africa Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 110. Africa Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 111. Africa Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 112. Africa Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 113. North America Tissue Diagnostics, by Country USD Billion (2017-2022)
  • Table 114. North America Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 115. North America Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 116. North America Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 117. North America Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 118. United States Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 119. United States Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 120. United States Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 121. United States Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 122. Canada Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 123. Canada Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 124. Canada Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 125. Canada Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 126. Mexico Tissue Diagnostics, by Type USD Billion (2017-2022)
  • Table 127. Mexico Tissue Diagnostics, by Application USD Billion (2017-2022)
  • Table 128. Mexico Tissue Diagnostics, by Technology USD Billion (2017-2022)
  • Table 129. Mexico Tissue Diagnostics, by End User USD Billion (2017-2022)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Tissue Diagnostics: by Type(USD Billion)
  • Table 141. Tissue Diagnostics Consumables(Antibodies Kits, Reagents, Probes) , by Region USD Billion (2023-2028)
  • Table 142. Tissue Diagnostics Instruments (Slide Staining System, Scanner) , by Region USD Billion (2023-2028)
  • Table 143. Tissue Diagnostics: by Application(USD Billion)
  • Table 144. Tissue Diagnostics Breast Cancer , by Region USD Billion (2023-2028)
  • Table 145. Tissue Diagnostics Gastric Cancer , by Region USD Billion (2023-2028)
  • Table 146. Tissue Diagnostics Lymphoma , by Region USD Billion (2023-2028)
  • Table 147. Tissue Diagnostics Prostate Cancer , by Region USD Billion (2023-2028)
  • Table 148. Tissue Diagnostics Non-Small Cell Lung Cancer (NSCLC) , by Region USD Billion (2023-2028)
  • Table 149. Tissue Diagnostics Other Diseases , by Region USD Billion (2023-2028)
  • Table 150. Tissue Diagnostics: by Technology(USD Billion)
  • Table 151. Tissue Diagnostics Immunohistochemistry (IHC) , by Region USD Billion (2023-2028)
  • Table 152. Tissue Diagnostics In Situ Hybridization (ISH) , by Region USD Billion (2023-2028)
  • Table 153. Tissue Diagnostics Digital Pathology and Workflow Management , by Region USD Billion (2023-2028)
  • Table 154. Tissue Diagnostics Special Staining , by Region USD Billion (2023-2028)
  • Table 155. Tissue Diagnostics: by End User(USD Billion)
  • Table 156. Tissue Diagnostics Hospitals , by Region USD Billion (2023-2028)
  • Table 157. Tissue Diagnostics Ambulatory Surgical Centers , by Region USD Billion (2023-2028)
  • Table 158. Tissue Diagnostics Diagnostic Centers , by Region USD Billion (2023-2028)
  • Table 159. Tissue Diagnostics Research Laboratories , by Region USD Billion (2023-2028)
  • Table 160. South America Tissue Diagnostics, by Country USD Billion (2023-2028)
  • Table 161. South America Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 162. South America Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 163. South America Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 164. South America Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 165. Brazil Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 166. Brazil Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 167. Brazil Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 168. Brazil Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 169. Argentina Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 170. Argentina Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 171. Argentina Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 172. Argentina Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 173. Rest of South America Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 174. Rest of South America Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 175. Rest of South America Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 176. Rest of South America Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 177. Asia Pacific Tissue Diagnostics, by Country USD Billion (2023-2028)
  • Table 178. Asia Pacific Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 179. Asia Pacific Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 180. Asia Pacific Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 181. Asia Pacific Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 182. China Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 183. China Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 184. China Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 185. China Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 186. Japan Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 187. Japan Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 188. Japan Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 189. Japan Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 190. India Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 191. India Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 192. India Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 193. India Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 194. South Korea Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 195. South Korea Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 196. South Korea Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 197. South Korea Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 198. Taiwan Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 199. Taiwan Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 200. Taiwan Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 201. Taiwan Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 202. Australia Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 203. Australia Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 204. Australia Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 205. Australia Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 206. Rest of Asia-Pacific Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 207. Rest of Asia-Pacific Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 208. Rest of Asia-Pacific Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 209. Rest of Asia-Pacific Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 210. Europe Tissue Diagnostics, by Country USD Billion (2023-2028)
  • Table 211. Europe Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 212. Europe Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 213. Europe Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 214. Europe Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 215. Germany Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 216. Germany Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 217. Germany Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 218. Germany Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 219. France Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 220. France Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 221. France Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 222. France Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 223. Italy Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 224. Italy Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 225. Italy Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 226. Italy Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 227. United Kingdom Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 228. United Kingdom Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 229. United Kingdom Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 230. United Kingdom Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 231. Netherlands Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 232. Netherlands Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 233. Netherlands Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 234. Netherlands Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 235. Rest of Europe Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 236. Rest of Europe Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 237. Rest of Europe Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 238. Rest of Europe Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 239. MEA Tissue Diagnostics, by Country USD Billion (2023-2028)
  • Table 240. MEA Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 241. MEA Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 242. MEA Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 243. MEA Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 244. Middle East Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 245. Middle East Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 246. Middle East Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 247. Middle East Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 248. Africa Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 249. Africa Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 250. Africa Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 251. Africa Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 252. North America Tissue Diagnostics, by Country USD Billion (2023-2028)
  • Table 253. North America Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 254. North America Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 255. North America Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 256. North America Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 257. United States Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 258. United States Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 259. United States Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 260. United States Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 261. Canada Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 262. Canada Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 263. Canada Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 264. Canada Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 265. Mexico Tissue Diagnostics, by Type USD Billion (2023-2028)
  • Table 266. Mexico Tissue Diagnostics, by Application USD Billion (2023-2028)
  • Table 267. Mexico Tissue Diagnostics, by Technology USD Billion (2023-2028)
  • Table 268. Mexico Tissue Diagnostics, by End User USD Billion (2023-2028)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tissue Diagnostics: by Type USD Billion (2017-2022)
  • Figure 5. Global Tissue Diagnostics: by Application USD Billion (2017-2022)
  • Figure 6. Global Tissue Diagnostics: by Technology USD Billion (2017-2022)
  • Figure 7. Global Tissue Diagnostics: by End User USD Billion (2017-2022)
  • Figure 8. South America Tissue Diagnostics Share (%), by Country
  • Figure 9. Asia Pacific Tissue Diagnostics Share (%), by Country
  • Figure 10. Europe Tissue Diagnostics Share (%), by Country
  • Figure 11. MEA Tissue Diagnostics Share (%), by Country
  • Figure 12. North America Tissue Diagnostics Share (%), by Country
  • Figure 13. Global Tissue Diagnostics share by Players 2022 (%)
  • Figure 14. Global Tissue Diagnostics share by Players (Top 3) 2022(%)
  • Figure 15. Global Tissue Diagnostics share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Roche (Switzerland) Revenue: by Geography 2022
  • Figure 19. Danaher (United States) Revenue, Net Income and Gross profit
  • Figure 20. Danaher (United States) Revenue: by Geography 2022
  • Figure 21. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 22. Thermo Fisher Scientific (United States) Revenue: by Geography 2022
  • Figure 23. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 24. Abbott (United States) Revenue: by Geography 2022
  • Figure 25. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 26. Agilent Technologies (United States) Revenue: by Geography 2022
  • Figure 27. ABCAM (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. ABCAM (United Kingdom) Revenue: by Geography 2022
  • Figure 29. Merck KGAA (Germany)\ Revenue, Net Income and Gross profit
  • Figure 30. Merck KGAA (Germany)\ Revenue: by Geography 2022
  • Figure 31. BD (United States) Revenue, Net Income and Gross profit
  • Figure 32. BD (United States) Revenue: by Geography 2022
  • Figure 33. Hologic (United States) Revenue, Net Income and Gross profit
  • Figure 34. Hologic (United States) Revenue: by Geography 2022
  • Figure 35. Qiagen (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Qiagen (Germany) Revenue: by Geography 2022
  • Figure 37. Global Tissue Diagnostics: by Type USD Billion (2023-2028)
  • Figure 38. Global Tissue Diagnostics: by Application USD Billion (2023-2028)
  • Figure 39. Global Tissue Diagnostics: by Technology USD Billion (2023-2028)
  • Figure 40. Global Tissue Diagnostics: by End User USD Billion (2023-2028)
  • Figure 41. South America Tissue Diagnostics Share (%), by Country
  • Figure 42. Asia Pacific Tissue Diagnostics Share (%), by Country
  • Figure 43. Europe Tissue Diagnostics Share (%), by Country
  • Figure 44. MEA Tissue Diagnostics Share (%), by Country
  • Figure 45. North America Tissue Diagnostics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Roche (Switzerland)
  • Danaher (United States)
  • Thermo Fisher Scientific (United States)
  • Abbott (United States)
  • Agilent Technologies (United States)
  • ABCAM (United Kingdom)
  • Merck KGAA (Germany)\
  • BD (United States)
  • Hologic (United States)
  • Qiagen (Germany)
Additional players considered in the study are as follows:
Bio Rad (United States) , Biomeriux (France) , BioSB (United States),
Select User Access Type

Key Highlights of Report


Jun 2023 200 Pages 73 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Tissue Diagnostics Quantitative research analysis
Global Tissue Diagnostics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Tissue Diagnostics Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Tissue Diagnostics market is dominated by United States Players and may generate healthy valuation by 2028.
  • The growing number of cancer incidence across the globe
  • Rising healthcare expenditure
dominated the Tissue Diagnostics market. This is attributable to growing trend of "Ongoing innovation and technological advancement on tissue diagnostics"

Know More About Global Tissue Diagnostics Report?

Have a Query? Click Here

Other Related Reports

Electroceuticals/Bioelectric Medicine Comprehensive Study by Type (Pacemakers, Cochlear Implants, Spinal Cord Stimulators, Implantable Cardioverter Defibrillators, Deep Brain Stimulators, Transcutane...
$ 3800
Hypopigmentation Disorder Treatment Comprehensive Study by Type (Topical Drugs, Laser, Chemical Peels, Microdermabrasion, Others), Application (Vitiligo, Albinism, Others), End-Use (Hospitals, Aesthe...
$ 3350
Medical Device Security Comprehensive Study by Type (Application Security, Endpoint Security, Network Security, Cloud Security, Other Security Types (Email, Web, and Database Security)), Application ...
$ 3750
Renal Biomarker Comprehensive Study by Type (Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers, Pharmacodynamic Biomarkers), Application (Hospital, Diagnostic Laboratory, Other), Di...
$ 3750
Online Weight Loss Programs Comprehensive Study by Type (Diet Weight Loss Programs, Exercise Weight Loss Programs, Others), Platform (Web, Mobile Apps), Subscription (Monthly, Quarterly, Annual), End...
$ 3500
Ambulance Services Comprehensive Study by Type (Emergency Ambulance Services, General Ambulance Services), Application (Pre-hospital Support, Post-hospital Support), Services Sector (Private, Public)...
$ 3750